{"title":"乳房切除术后放疗对新辅助化疗后ypN0乳腺癌患者局部复发和生存的影响:一项综合荟萃分析和系统评价。","authors":"Fangjie Ding, Junfeng Zhao, Xue Wu, Xiaoman Liu, Yunxing Yang, Ying Li, Lili Qiao, Yingying Zhang","doi":"10.4103/jcrt.jcrt_1279_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The necessity of postmastectomy radiotherapy (PMRT) following neoadjuvant chemotherapy (NAC) in patients with ypN0 breast cancer remains a controversial clinical issue. To elucidate this issue, the present study performed a systematic review and meta-analysis, focusing on studies of clinically lymph node-negative patients exhibiting a favorable pathologic response to NAC.</p><p><strong>Materials and methods: </strong>After a comprehensive literature search of PubMed and major oncology congress abstracts, 16 studies that met the inclusion criteria were included. A fixed or random effects model was used to assess the impact of PMRT on the local recurrence rate (LRR) and survival outcomes, where appropriate.</p><p><strong>Results: </strong>The pooled data from ten studies indicated that PMRT significantly reduced the LRR in patients with ypN0 breast cancer (risk ratio [RR], 0.52; 95% confidence interval [CI], 0.41-0.67, P < 0.00001). Moreover, a marginal increase in the overall survival (OS) rates was observed in nine studies (RR, 1.01; 95% CI, 1.00-1.02, P = 0.006), whereas no significant effect on disease-free survival (DFS) was found in six studies (RR, 1.01; 95% CI, 0.95-1.08, P = 0.72).</p><p><strong>Conclusions: </strong>Our findings suggest that PMRT is associated with reduced LRR and slightly improved OS in patients with ypN0 breast cancer. However, prospective studies are needed to provide more evidence and inform clinical decision-making.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"477-482"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.\",\"authors\":\"Fangjie Ding, Junfeng Zhao, Xue Wu, Xiaoman Liu, Yunxing Yang, Ying Li, Lili Qiao, Yingying Zhang\",\"doi\":\"10.4103/jcrt.jcrt_1279_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The necessity of postmastectomy radiotherapy (PMRT) following neoadjuvant chemotherapy (NAC) in patients with ypN0 breast cancer remains a controversial clinical issue. To elucidate this issue, the present study performed a systematic review and meta-analysis, focusing on studies of clinically lymph node-negative patients exhibiting a favorable pathologic response to NAC.</p><p><strong>Materials and methods: </strong>After a comprehensive literature search of PubMed and major oncology congress abstracts, 16 studies that met the inclusion criteria were included. A fixed or random effects model was used to assess the impact of PMRT on the local recurrence rate (LRR) and survival outcomes, where appropriate.</p><p><strong>Results: </strong>The pooled data from ten studies indicated that PMRT significantly reduced the LRR in patients with ypN0 breast cancer (risk ratio [RR], 0.52; 95% confidence interval [CI], 0.41-0.67, P < 0.00001). Moreover, a marginal increase in the overall survival (OS) rates was observed in nine studies (RR, 1.01; 95% CI, 1.00-1.02, P = 0.006), whereas no significant effect on disease-free survival (DFS) was found in six studies (RR, 1.01; 95% CI, 0.95-1.08, P = 0.72).</p><p><strong>Conclusions: </strong>Our findings suggest that PMRT is associated with reduced LRR and slightly improved OS in patients with ypN0 breast cancer. However, prospective studies are needed to provide more evidence and inform clinical decision-making.</p>\",\"PeriodicalId\":94070,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\"21 2\",\"pages\":\"477-482\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_1279_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_1279_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:ypN0乳腺癌患者在新辅助化疗(NAC)后是否需要乳房切除术后放疗(PMRT)仍是一个有争议的临床问题。为了阐明这一问题,本研究进行了系统回顾和荟萃分析,重点研究临床淋巴结阴性患者对NAC表现出良好的病理反应。材料和方法:通过对PubMed和主要肿瘤学大会摘要的综合文献检索,纳入了16项符合纳入标准的研究。在适当的情况下,采用固定或随机效应模型评估PMRT对局部复发率(LRR)和生存结果的影响。结果:10项研究的汇总数据显示,PMRT显著降低了ypN0乳腺癌患者的LRR(风险比[RR], 0.52;95%可信区间[CI], 0.41-0.67, P < 0.00001)。此外,在9项研究中观察到总生存率(OS)的边际增加(RR, 1.01;95% CI, 1.00-1.02, P = 0.006),而6项研究未发现对无病生存(DFS)有显著影响(RR, 1.01;95% ci, 0.95-1.08, p = 0.72)。结论:我们的研究结果表明,PMRT与ypN0乳腺癌患者的LRR降低和OS略有改善相关。然而,需要前瞻性研究来提供更多的证据并为临床决策提供信息。
Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.
Background: The necessity of postmastectomy radiotherapy (PMRT) following neoadjuvant chemotherapy (NAC) in patients with ypN0 breast cancer remains a controversial clinical issue. To elucidate this issue, the present study performed a systematic review and meta-analysis, focusing on studies of clinically lymph node-negative patients exhibiting a favorable pathologic response to NAC.
Materials and methods: After a comprehensive literature search of PubMed and major oncology congress abstracts, 16 studies that met the inclusion criteria were included. A fixed or random effects model was used to assess the impact of PMRT on the local recurrence rate (LRR) and survival outcomes, where appropriate.
Results: The pooled data from ten studies indicated that PMRT significantly reduced the LRR in patients with ypN0 breast cancer (risk ratio [RR], 0.52; 95% confidence interval [CI], 0.41-0.67, P < 0.00001). Moreover, a marginal increase in the overall survival (OS) rates was observed in nine studies (RR, 1.01; 95% CI, 1.00-1.02, P = 0.006), whereas no significant effect on disease-free survival (DFS) was found in six studies (RR, 1.01; 95% CI, 0.95-1.08, P = 0.72).
Conclusions: Our findings suggest that PMRT is associated with reduced LRR and slightly improved OS in patients with ypN0 breast cancer. However, prospective studies are needed to provide more evidence and inform clinical decision-making.